These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 10744342)

  • 1. Effect of dopamine agonists and antagonists on the lorazepam withdrawal syndrome in rats.
    Nath C; Saxena RC; Gupta MB
    Clin Exp Pharmacol Physiol; 2000 Mar; 27(3):167-71. PubMed ID: 10744342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of central histaminergic system in lorazepam withdrawal syndrome in rats.
    Nath C; Gupta MB
    Pharmacol Biochem Behav; 2001 Apr; 68(4):777-82. PubMed ID: 11526976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of inhibitory effect of diphenhydramine on benzodiazepine dependence in rats.
    Nath C; Patnaik GK; Saxena RC; Gupta MB
    Indian J Physiol Pharmacol; 1997 Jan; 41(1):42-6. PubMed ID: 10225031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of calcium channel blockers on withdrawal syndrome of lorazepam in rats.
    Gupta MB; Nath C; Patnaik GK; Saxena RC
    Indian J Med Res; 1996 Jun; 103():310-4. PubMed ID: 8707372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Locomotor activity and dopamine synthesis following 1 and 15 days of withdrawal from repeated apomorphine treatments.
    Rowlett JK; Mattingly BA; Bardo MT
    Pharmacol Biochem Behav; 1997; 57(1-2):13-8. PubMed ID: 9164548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensorimotor gating effects produced by repeated dopamine agonists in a paradigm favoring environmental conditioning.
    Feifel D; Priebe K; Johnstone-Miller E; Morgan CJ
    Psychopharmacology (Berl); 2002 Jul; 162(2):138-46. PubMed ID: 12110991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physical dependence on diazepam and lorazepam in the dog.
    McNicholas LF; Martin WR; Cherian S
    J Pharmacol Exp Ther; 1983 Sep; 226(3):783-9. PubMed ID: 6136601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of 6 different methods for lorazepam withdrawal. A controlled study, hydroxyzine versus placebo].
    Lemoine P; Touchon J; Billardon M
    Encephale; 1997; 23(4):290-9. PubMed ID: 9417395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic treatment with the D1 receptor antagonist, SCH 23390, and the D2 receptor antagonist, raclopride, in cebus monkeys withdrawn from previous haloperidol treatment. Extrapyramidal syndromes and dopaminergic supersensitivity.
    Lublin H; Gerlach J; Peacock L
    Psychopharmacology (Berl); 1993; 112(2-3):389-97. PubMed ID: 7871047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of ipsapirone treatment compared with lorazepam: discontinuation effects.
    Busto UE; Naranjo CA; Bremner KE; Peachey JE; Bologa M
    J Psychiatry Neurosci; 1998 Jan; 23(1):35-44. PubMed ID: 9505058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of SCH 23390, raclopride, and haloperidol on morphine withdrawal-induced aggression in male mice.
    Rodríguez-Arias M; Pinazo J; Miñarro J; Stinus L
    Pharmacol Biochem Behav; 1999 Sep; 64(1):123-30. PubMed ID: 10495006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential influence of D1 and D2 dopamine receptors on acute opiate withdrawal in guinea-pig isolated ileum.
    Capasso A; Sorrentino L
    Br J Pharmacol; 1997 Mar; 120(6):1001-6. PubMed ID: 9134209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The role of dopamine neurotransmission on the development of ethanol dependence and course of abstinence syndrome].
    Samochowiec J
    Ann Acad Med Stetin; 1994; 40():195-217. PubMed ID: 7503446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyamemazine decreases ethanol intake in rats and convulsions during ethanol withdrawal syndrome in mice.
    Naassila M; Legrand E; d'Alche-Birée F; Daoust M
    Psychopharmacology (Berl); 1998 Dec; 140(4):421-8. PubMed ID: 9888617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The behavioural effects of pramipexole, a novel dopamine receptor agonist.
    Maj J; Rogóz Z; Skuza G; Kołodziejczyk K
    Eur J Pharmacol; 1997 Apr; 324(1):31-7. PubMed ID: 9137910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of SKF-38393, a dopamine D1 receptor agonist on expression of amphetamine-induced behavioral sensitization and expression of immediate early gene arc in prefrontal cortex of rats.
    Moro H; Sato H; Ida I; Oshima A; Sakurai N; Shihara N; Horikawa Y; Mikuni M
    Pharmacol Biochem Behav; 2007 May; 87(1):56-64. PubMed ID: 17499349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered activity of midbrain dopamine neurons following 7-day withdrawal from chronic cocaine abuse is normalized by D2 receptor stimulation during the early withdrawal phase.
    Lee TH; Gao WY; Davidson C; Ellinwood EH
    Neuropsychopharmacology; 1999 Jul; 21(1):127-36. PubMed ID: 10379527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerance and withdrawal after chronic lorazepam treatment in rats.
    van der Laan JW; Jansen van't Land C; de Groot G
    Eur Neuropsychopharmacol; 1993 Dec; 3(4):521-31. PubMed ID: 8111226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeated quinpirole treatment: locomotor activity, dopamine synthesis, and effects of selective dopamine antagonists.
    Rowlett JK; Mattingly BA; Bardo MT
    Synapse; 1995 Jul; 20(3):209-16. PubMed ID: 7570352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modification of naloxone-induced withdrawal signs by dextromethorphan in morphine-dependent mice.
    Farzin D
    Eur J Pharmacol; 1999 Jul; 377(1):35-42. PubMed ID: 10448923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.